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tially treatment of tauopathies such as Alzheimer’s disease, progressive supranuclear palsy, cortico-
basal syndrome, chronic traumatic encephalopathy, and some variants of frontotemporal lobar
degeneration. The assessment of tau deposition in the brain over time will allow a deeper understand-
ing of the relationship between tau and other variables such as cognition, genotype, and neurodegen-
eration, as well as assessing the role tau plays in ageing. Preliminary human studies suggest that tau
imaging could also be used as a diagnostic, prognostic, and theranostic biomarker, as well as a sur-
rogate marker for target engagement, patient recruitment, and efficacy monitoring for disease-
specific therapeutic trials.
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